Efficacy and Toxicity Seen With MIRV in Ovarian Cancer ...Middle East

Medscape - News
Efficacy and Toxicity Seen With MIRV in Ovarian Cancer
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Efficacy and Toxicity Seen With MIRV in Ovarian Cancer )

Apple Storegoogle play

Also on site :